MedMira's rapid HIV test gets headstart in China
This article was originally published in Clinica
Canadian in vitro diagnostics firm MedMira has beaten a path to a potentially lucrative market in China. The company has just become the first to gain State Drug Administration (SDA) approval for a rapid, point of care HIV test.
You may also be interested in...
Oncologic Drugs Advisory Committee will consider whether a statistically significant benefit on progression-free survival, but no survival advantage, is enough to secure a first-line lung cancer indication for ramucirumab.
Whoever takes over as chair of the Medicines and Healthcare products Regulatory Agency will play a key role in its plans to deliver a program of “ambitious business change.”
Perrigo has received US FDA approval for a generic version of Teva’s ProAir albuterol inhaler. The firm is immediately launching a “limited quantity” but is also ramping up production with partner Catalent to meet future demand.